news
New measures to minimise animal testing to be implemented in Europe
The European Medicines Agency is promoting three principles – replace, reduce and refine – to reduce animal testing in medicine development.
List view / Grid view
European Medicines Agency (EMA)
article
Radiochemistry and drug synthesis ‘in a flash’
Conventional methods for radiolabelling proteins are time consuming and difficult to automate. In this article, Jason P. Holland discusses how combining photochemistry with radiochemistry enables development of radiolabelled proteins far more quickly and easily – literally in a flash of light.
news
EMA’s building approval process in Amsterdam initiated
New permanent building to be completed by 15 November 2019...
news
EMA discusses future Amsterdam premises
The EMA Management Board have met in an extraordinary session to discuss EMA’s future premises in Amsterdam...
news
EMA to relocate to Amsterdam, the Netherlands
The EMA will relocate to Amsterdam in the Netherlands. The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest...
news
Could Milan be the new home for the EMA?
Wayne Pines, President of Healthcare at APCO Worldwide in Washington DC and a former Associate Commissioner of the FDA believes Milan is a logical choice for the relocation of the EMA...
news
Wellcome Trust gives Polyphor CHF 2.3 million for antibiotic development
Polyphor has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates.
news
New drug could prevent graft loss in pancreatic islet transplantation
5 December 2016 | By Niamh Louise Marriott, Digital Editor
In a rodent model of islet transplantation, ARA 290 markedly reduced transplantation-induced inflammation, resulting in a marked increase in islet survival...
news
ESCMID and ASM’s review need for new strategies and tactics to fight antimicrobial resistance
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the American Society for Microbiology (ASM) have just closed a joint conference in Vienna, which aimed to help researchers accelerate the development of new antimicrobials and to shed light on the challenges associated with antimicrobial resistance.
article
UK life sciences are stronger in the EU, says BioIndustry Association
16 March 2016 | By Steve Bates, BioIndustry Association (BIA) Chief Executive
Here, Steve Bates, Chief Executive of the BioIndustry Association (BIA), makes a case for the UK remaining in the EU from the perspective of the life sciences sector...
news
FDA and EMA grants orphan drug designation to recAP for the treatment of hypophosphatasia
9 June 2015 | By Victoria White
AM‐Pharma has announced that the FDA and EMA have both granted orphan designation status to recAP for the treatment of hypophosphatasia...
news
European CHMP adopts positive opinion for Gilead’s zydelig® (idelalisib) for the treatment of chronic lymphocytic leukemia and follicular lymphoma
25 July 2014 | By Gilead
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for Zydelig®...
news
Sanofi reports positive Phase 3 results for Toujeo®
19 June 2014 | By Sanofi
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...
article
Foreword: Enabling the development of new medicines
Over the past few years, the landscape of medicines development has shifted. We have seen a decline in the research and development productivity of the pharmaceutical industry. Innovator drug developers have been confronted with the current pressure on healthcare budgets, as well as a wave of patent expiries for blockbuster…
news
EMA and Australian regulator strengthen collaboration in the area of orphan medicines
7 April 2014 | By The European Medicines Agency
In a meeting at the European Medicines Agency on 4 April 2014, the EMA’s Executive Director, Prof. Guido Rasi, and the National Manager of the Australian Therapeutic Goods AdministrationExternal link icon, Prof. John Skerritt, announced that the two regulators have agreed to share the full assessment reports...